Giving Vitamin D often reduced COVID Mortality– Review of 11 studies

Therapeutic Vitamin D Supplementation Following COVID-19 Diagnosis: Where Do We Stand?—A Systematic Review

J. Pers. Med. 2022, 12(3), 419; https://doi.org/10.3390/jpm12030419

by Angelina Bania 1ORCID,Konstantinos Pitsikakis 2,Georgios Mavrovounis 3,*,Maria Mermiri 4ORCID,Eleftherios T. Beltsios 3ORCID,Antonis Adamou 5ORCID,Vasiliki Konstantaki 6,Demosthenes Makris 7,Vasiliki Tsolaki 7ORCID,Konstantinos Gourgoulianis 8 andIoannis Pantazopoulos 3ORCID

Semi-activated vitamin D studies are highlighted in yellow

Mortality often reduced if given enough vitamin D or use semi-activated form

Vitamin D has known immunomodulatory activity and multiple indications exist supporting its potential use against SARS-CoV-2 infection in the setting of the current pandemic. The purpose of this systematic review is to examine the efficacy of vitamin D administered to adult patients following COVID-19 diagnosis in terms of length of hospital stay, intubation, ICU admission and mortality rates. Therefore, PubMed and Scopus databases were searched for original articles referring to the aforementioned parameters. Of the 1376 identified studies, eleven were finally included. Vitamin D supplements, and especially calcifediol, were shown to be useful in significantly reducing ICU admissions and/or mortality in four of the studies, but not in diminishing the duration of hospitalization of COVID-19 patients. Due to the large variation in vitamin D supplementation schemes no absolute conclusions can be drawn until larger randomized controlled trials are completed. However, calcifediol administered to COVID-19 patients upon diagnosis represents by far the most promising agent and should be the focus of upcoming research efforts.

📄 Download the PDF from VitaminDWiki

Note: Studies chosen were <1% of the studies available

Mortality and Virus studies

{category}